May. 20 at 5:27 PM
$MSCLF only a couple more days for 1b results, and reminder: this is a dystrophin-independent pathway they are targeting that will apply to all DMD patients. They will have US sites up and running after FDA grants IND, if you know a DMD kid, let them know of this treatment.
"Satellos will share data from its Phase 1b study in adult Duchenne muscle disease (DMD) patients in the second quarter, said Chief Executive Frank Gleeson."
"As a company, we believe we are well positioned to advance our novel drug into a randomized, placebo-controlled Phase 2 POC [proof-of-concept] trial in pediatric DMD patients as our next major development step," Gleeson said. "This study will be designed to further assess the safety of SAT-3247 in a key pediatric population, while exploring its possible utility in restoring the body's ability to repair and regenerate damaged or lost muscle."
$CAPR $SRPT $DYN
